Justin Creel
Executive Director, Device Development Genentech
Justin Creel, Ph.D. is Executive Director of Device Development at Genentech, where he leads strategy and execution for small-volume ocular drug delivery systems supporting advanced cell and gene therapies. With more than 20 years of experience spanning medical devices, drug delivery, and biotechnology, he has held senior leadership roles at Genentech, Novartis, Gyroscope Therapeutics, and other innovative healthcare companies. His expertise encompasses device innovation, combination products, clinical integration, technology transfer, manufacturing scale-up, and regulatory strategy. Previously, as VP of Device Development at Gyroscope Therapeutics, he led development of novel ocular delivery technologies for retinal gene therapy. Justin holds a Ph.D. in Biomedical Engineering from UC Davis.
Seminars
- Join experienced developers and researchers of long-acting ocular therapies to explore lessons from ongoing development to avoid common pitfalls and accelerate development
- Understand why promising durability data often fails to translate from preclinical studies into clinical success and learn how to generate more predictive evidence earlier in development
- Learn how to overcome formulation, delivery, inflammation, and safety challenges while improving durability, efficacy, and patient experience
- Discuss practical strategies for managing development risk, investment timelines, and key decision points to improve long-term clinical and commercial success
